Cardiovascular risk factors and their interactions in hypertensives
- PMID: 1797997
Cardiovascular risk factors and their interactions in hypertensives
Abstract
Numerous intervention trials have demonstrated clear benefits when patients with hypertension have been treated with antihypertensive drugs. During the last five years, however, community-based studies from Dalby, Gothenburg and Glasgow have reported a high remaining risk of cardiovascular (especially cardiac) disease, even though the hypertensive patients have been well cared for and their blood pressure controlled. There may be several possible explanations for the high remaining risk. First, long-standing hypertension may have caused irreversible cardiovascular change and atherosclerosis, which contribute to the increased risk even when the elevated arterial blood pressure has been reduced to normotensive levels. Another possible explanation is that the antihypertensive drugs themselves, in addition to their desired and beneficial antihypertensive effect, have some adverse effects. Thus, by elevating serum lipoproteins or by lowering serum potassium, some agents could increase the risk of cardiovascular complications and, to a certain extent, offset the beneficial effects of lowering blood pressure. Different drugs may, of course, also differ in their ability to prevent cardiovascular disease. In the studies mentioned above, blood pressure had not been reduced to strictly normotensive levels. This may be a third reason for the high remaining risks. A fourth possibility is that other metabolic factors may be implicated, and it may be necessary to tackle other, non-biological factors, such as smoking, stress and unemployment, in order to reduce the excess risk in hypertensive patients. It is clearly necessary to focus on the overall risk profile of the patient, including smoking and alcohol habits, cholesterol level, diet, weight, etc., rather than the blood pressure level alone.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
ESH-ESC guidelines for the management of hypertension.Herz. 2006 Jun;31(4):331-8. doi: 10.1007/s00059-006-2829-3. Herz. 2006. PMID: 16810473
-
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.Can J Cardiol. 2004 Jan;20(1):31-40. Can J Cardiol. 2004. PMID: 14968141
-
[Cardiovascular risk factors and prevention in women: similarities and differences].Ital Heart J Suppl. 2001 Feb;2(2):125-41. Ital Heart J Suppl. 2001. PMID: 11255880 Review. Italian.
-
[Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Aug;25(8):710-4. Zhonghua Liu Xing Bing Xue Za Zhi. 2004. PMID: 15555399 Chinese.
-
Metabolic and cardiovascular characteristics of hypertension. Familial aspects.Cardiol Clin. 1995 Nov;13(4):539-47. Cardiol Clin. 1995. PMID: 8565017 Review.
Cited by
-
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.Br J Clin Pharmacol. 1995 May;39(5):471-6. doi: 10.1111/j.1365-2125.1995.tb04482.x. Br J Clin Pharmacol. 1995. PMID: 7669481 Free PMC article. Clinical Trial.
-
Community control of hypertension at work-site: epidemiological data of the Agusta project.Eur J Epidemiol. 1995 Oct;11(5):591-5. doi: 10.1007/BF01719314. Eur J Epidemiol. 1995. PMID: 8549736
-
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.Pharmacoeconomics. 1994 Oct;6(4):370-400. doi: 10.2165/00019053-199406040-00004. Pharmacoeconomics. 1994. PMID: 10147474 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical